Advertisement
Canada markets closed
  • S&P/TSX

    22,167.03
    +59.95 (+0.27%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • DOW

    39,807.37
    +47.29 (+0.12%)
     
  • CAD/USD

    0.7380
    -0.0006 (-0.09%)
     
  • CRUDE OIL

    83.11
    -0.06 (-0.07%)
     
  • Bitcoin CAD

    95,258.45
    -603.38 (-0.63%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,254.80
    +16.40 (+0.73%)
     
  • RUSSELL 2000

    2,124.55
    +10.20 (+0.48%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • NASDAQ

    16,379.46
    -20.06 (-0.12%)
     
  • VOLATILITY

    13.01
    0.00 (0.00%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • NIKKEI 225

    40,369.44
    +201.37 (+0.50%)
     
  • CAD/EUR

    0.6836
    -0.0007 (-0.10%)
     

Why Celgene Corporation Dropped Today

What happened

Celgene (NASDAQ: CELG) is down 10.2% at 12:09 p.m. Friday after announcing yesterday after the market closed that it was stopping a clinical trial testing GED-0301 (mongersen) in Crohn's disease because the drug doesn't appear to be helping patients.

So what

The decision comes after the data monitoring committee reviewed interim results during a futility analysis of the "overall benefit/risk" of GED-0301. Celgene noted that there were "no meaningful safety imbalances identified," so the issue must have been on the efficacy side.

In addition to stopping the phase 3 RESOLVE trial and the SUSTAIN extension trial that patients can transition into from RESOLVE, Celgene said it doesn't plan to run DEFINE, a second phase 3 trial that hasn't started yet.

Pills and pen on a paper that reads
Pills and pen on a paper that reads

Image source: Getty Images.

ADVERTISEMENT

There's still some hope for GED-0301 since it's also in a phase 2 trial in another inflammatory disease called ulcerative colitis. Celgene is going to wait for that data before deciding whether it's going to scrap the drug entirely.

This was a costly mistake for Celgene, which paid $710 million to privately held Nogra Pharma to get the drug. The only good news is that Celgene smartly set up the deal with milestone payments of $815 million, at least some of which it presumably won't have to pay with the failure in Chron's disease.

Now what

While a failure is bad news for any biotech, Celgene has enough drugs on the market and in the pipeline that losing GED-0301 shouldn't be a major problem.

In fact, Celgene has drugs in its pipeline that could treat the same diseases. Ozanimod is already in a phase 3 trial in patients with ulcerative colitis, and Celgene plans to start a phase 3 trial in Crohn's disease soon after reporting positive phase 2 data earlier this month. Celgene is also testing Otezla, which is approved to treat plaque psoriasis and psoriatic arthritis, in a phase 2 trial in patients with ulcerative colitis that should read out data by the end of the year. If the trial is positive, Celgene would start in a phase 3 program next year.

Success by Ozanimod and/or Otezla would deaden the blow from GED-0301 substantially.

More From The Motley Fool

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Celgene. The Motley Fool has a disclosure policy.